目的探讨替米沙坦干预对自发性高血压大鼠(SHR)血管组织血管紧张素转换酶2(ACE2)基因表达、一氧化氮(NO)及氧化应激水平的影响。方法选取10周龄SHR及其同源对照WKY大鼠,分别给予替米沙坦(5、10 mg.kg-1.d-1)或安慰剂,为期10周。采用West...目的探讨替米沙坦干预对自发性高血压大鼠(SHR)血管组织血管紧张素转换酶2(ACE2)基因表达、一氧化氮(NO)及氧化应激水平的影响。方法选取10周龄SHR及其同源对照WKY大鼠,分别给予替米沙坦(5、10 mg.kg-1.d-1)或安慰剂,为期10周。采用Western blot检测治疗后大鼠主动脉组织中ACE2蛋白及内皮型NO合酶(eNOS)磷酸化水平。分别采用硝酸还原酶比色法与硫代巴比妥酸比色法测定大鼠主动脉组织中NO和丙二醛(MDA)含量。结果与WKY对照组相比,SHR大鼠主动脉组织中ACE2蛋白和Ser1177-eNOS磷酸化水平明显降低(ACE2:0.39±0.05vs 1.00±0.06;p-eNOS:0.43±0.06 vs 1.00±0.04;P值均<0.01),伴NO水平下调及MDA含量增加(NO mmol.g-1protein:11.5±2.1 vs 27.8±4.9;MDA nmol.g-1 protein:393.9±17.9 vs 186.3±14.5;P值均<0.01),而经替米沙坦治疗后SHR低、高剂量治疗组大鼠主动脉组织中ACE2蛋白和Ser1177-eNOS磷酸化水平增加(ACE2:0.62±0.06,0.65±0.07 vs 0.39±0.05;p-eNOS:0.68±0.07,0.71±0.06 vs0.43±0.06;P值均<0.05),伴NO水平升高(19.2±3.3,23.9±3.2 vs 11.5±2.1 mmol.g-1protein;P值均<0.05)与MDA含量下调(271.9±16.1,249.2±19.6 vs 393.9±17.9nmol.g-1protein;P值均<0.05)。结论长期替米沙坦治疗通过提升高血压大鼠血管ACE2表达及eNOS磷酸化水平,可促使血管NO生成及氧化应激水平改善,提示替米沙坦对高血压具有一定的血管保护功效。展开更多
Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has precipitated multiple variants resistant to therapeutic antibodies.In this study,12 high-affinity antibodies were generated from convalescent donors in e...Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has precipitated multiple variants resistant to therapeutic antibodies.In this study,12 high-affinity antibodies were generated from convalescent donors in early outbreaks using immune antibody phage display libraries.Of them,two RBD-binding antibodies(F61 and H121)showed high-affinity neutralization against SARS-Co V-2,whereas three S2-target antibodies failed to neutralize SARS-Co V-2.Following structure analysis,F61 identified a linear epitope located in residues G446–S494,which overlapped with angiotensinconverting enzyme 2(ACE2)binding sites,while H121 recognized a conformational epitope located on the side face of RBD,outside from ACE2 binding domain.Hence the cocktail of the two antibodies achieved better performance of neutralization to SARS-Co V-2.Importantly,these two antibodies also showed efficient neutralizing activities to the variants including B.1.1.7 and B.1.351,and reacted with mutations of N501 Y,E484 K,and L452 R,indicated that it may also neutralize the recent India endemic strain B.1.617.The unchanged binding activity of F61 and H121 to RBD with multiple mutations revealed a broad neutralizing activity against variants,which mitigated the risk of viral escape.Our findings revealed the therapeutic basis of cocktail antibodies against constantly emerging SARS-Co V-2 variants and provided promising candidate antibodies to clinical treatment of COVID-19 patients infected with broad SARS-Co V-2 variants.展开更多
The rapid spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) in recent years not only caused a global pandemic but resulted in enormous social,economic,and health burdens worldwide.Despite considera...The rapid spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) in recent years not only caused a global pandemic but resulted in enormous social,economic,and health burdens worldwide.Despite considerable efforts to combat coronavirus disease 2019(COVID-19),various SARS-CoV-2 variants have emerged,and their underlying mechanisms of pathogenicity remain largely unknown.Furthermore,effective therapeutic drugs are still under development.Thus,an ideal animal model is crucial for studying the pathogenesis of COVID-19 and for the preclinical evaluation of vaccines and antivirals against SARS-CoV-2 and variant infections.Currently,several animal models,including mice,hamsters,ferrets,and nonhuman primates(NHPs),have been established to study COVID-19.Among them,ferrets are naturally susceptible to SARS-CoV-2 infection and are considered suitable for COVID-19 study.Here,we summarize recent developments and application of SARS-CoV-2 ferret models in studies on pathogenesis,therapeutic agents,and vaccines,and provide a perspective on the role of these models in preventing COVID-19 spread.展开更多
The mechanism of how SARS-CoV-2 causes severe multi-organ failure is largely unknown. Acute kidney injury(AKI) is one of the frequent organ damage in severe COVID-19 patients. Previous studies have shown that human re...The mechanism of how SARS-CoV-2 causes severe multi-organ failure is largely unknown. Acute kidney injury(AKI) is one of the frequent organ damage in severe COVID-19 patients. Previous studies have shown that human renal tubule cells could be the potential host cells targeted by SARS-CoV-2. Traditional cancer cell lines or immortalized cell lines are genetically and phenotypically different from host cells. Animal models are widely used, but often fail to reflect a physiological and pathogenic status because of species tropisms. There is an unmet need for normal human epithelial cells for disease modeling. In this study, we successfully established long term cultures of normal human kidney proximal tubule epithelial cells(KPTECs) in 2 D and 3 D culture systems using conditional reprogramming(CR) and organoids techniques.These cells had the ability to differentiate and repair DNA damage, and showed no transforming property. Importantly, the CR KPTECs maintained lineage function with expression of specific transporters(SLC34 A3 and cubilin). They also expressed angiotensin-converting enzyme 2(ACE2), a receptor for SARS-CoV and SARS-CoV-2. In contrast, cancer cell line did not express endogenous SLC34 A3, cubilin and ACE2. Very interestingly, ACE2 expression was around twofold higher in 3 D organoids culture compared to that in 2 D CR culture condition. Pseudovirion assays demonstrated that SARS-CoV spike(S) protein was able to enter CR cells with luciferase reporter. This integrated 2 D CR and 3 D organoid cultures provide a physiological ex vivo model to study kidney functions, innate immune response of kidney cells to viruses, and a novel platform for drug discovery and safety evaluation.展开更多
Global prevalence of coronavirus disease 2019(COVID-19)calls for an urgent development of anti-viral regime.Compared with the development of new drugs,drug repurposing can significantly reduce the cost,time,and safety...Global prevalence of coronavirus disease 2019(COVID-19)calls for an urgent development of anti-viral regime.Compared with the development of new drugs,drug repurposing can significantly reduce the cost,time,and safety risks.Given the fact that coronavirus harnesses spike protein to invade host cells through angiotensinconverting enzyme 2(ACE2),hence we see if any previous anti-virtual compounds can block spike-ACE2 interaction and inhibit the virus entry.The results of molecular docking and molecular dynamic simulations revealed that remdesivir exhibits better than expected anti-viral invasion potential against COVID-19 among the three types of compounds including remdesivir,tenofovir and lopinavir.In addition,a positive correlation between the surface area occupied by remdesivir and anti-viral invasion potential was also found.As such,the structure of remdesivir was modified by linking an N-benzyl substituted diamidine derivative to its hydroxyl group through an ester bond.It was found that this compound has a higher anti-viral invasion potential and greater specificity.展开更多
文摘目的探讨替米沙坦干预对自发性高血压大鼠(SHR)血管组织血管紧张素转换酶2(ACE2)基因表达、一氧化氮(NO)及氧化应激水平的影响。方法选取10周龄SHR及其同源对照WKY大鼠,分别给予替米沙坦(5、10 mg.kg-1.d-1)或安慰剂,为期10周。采用Western blot检测治疗后大鼠主动脉组织中ACE2蛋白及内皮型NO合酶(eNOS)磷酸化水平。分别采用硝酸还原酶比色法与硫代巴比妥酸比色法测定大鼠主动脉组织中NO和丙二醛(MDA)含量。结果与WKY对照组相比,SHR大鼠主动脉组织中ACE2蛋白和Ser1177-eNOS磷酸化水平明显降低(ACE2:0.39±0.05vs 1.00±0.06;p-eNOS:0.43±0.06 vs 1.00±0.04;P值均<0.01),伴NO水平下调及MDA含量增加(NO mmol.g-1protein:11.5±2.1 vs 27.8±4.9;MDA nmol.g-1 protein:393.9±17.9 vs 186.3±14.5;P值均<0.01),而经替米沙坦治疗后SHR低、高剂量治疗组大鼠主动脉组织中ACE2蛋白和Ser1177-eNOS磷酸化水平增加(ACE2:0.62±0.06,0.65±0.07 vs 0.39±0.05;p-eNOS:0.68±0.07,0.71±0.06 vs0.43±0.06;P值均<0.05),伴NO水平升高(19.2±3.3,23.9±3.2 vs 11.5±2.1 mmol.g-1protein;P值均<0.05)与MDA含量下调(271.9±16.1,249.2±19.6 vs 393.9±17.9nmol.g-1protein;P值均<0.05)。结论长期替米沙坦治疗通过提升高血压大鼠血管ACE2表达及eNOS磷酸化水平,可促使血管NO生成及氧化应激水平改善,提示替米沙坦对高血压具有一定的血管保护功效。
基金supported by the National Science and Technology Major Project(2018ZX10711-001)(2017YFA0205100)。
文摘Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has precipitated multiple variants resistant to therapeutic antibodies.In this study,12 high-affinity antibodies were generated from convalescent donors in early outbreaks using immune antibody phage display libraries.Of them,two RBD-binding antibodies(F61 and H121)showed high-affinity neutralization against SARS-Co V-2,whereas three S2-target antibodies failed to neutralize SARS-Co V-2.Following structure analysis,F61 identified a linear epitope located in residues G446–S494,which overlapped with angiotensinconverting enzyme 2(ACE2)binding sites,while H121 recognized a conformational epitope located on the side face of RBD,outside from ACE2 binding domain.Hence the cocktail of the two antibodies achieved better performance of neutralization to SARS-Co V-2.Importantly,these two antibodies also showed efficient neutralizing activities to the variants including B.1.1.7 and B.1.351,and reacted with mutations of N501 Y,E484 K,and L452 R,indicated that it may also neutralize the recent India endemic strain B.1.617.The unchanged binding activity of F61 and H121 to RBD with multiple mutations revealed a broad neutralizing activity against variants,which mitigated the risk of viral escape.Our findings revealed the therapeutic basis of cocktail antibodies against constantly emerging SARS-Co V-2 variants and provided promising candidate antibodies to clinical treatment of COVID-19 patients infected with broad SARS-Co V-2 variants.
基金supported by the S&T Program of Hebei(20277705D and 20372601D)Natural Science Foundation of Hebei Province,China (H2020206352)+2 种基金Science and Technology Project of Hebei Education Department (QN2018150)Hebei Medical Science Research Project (20220973)Chinese Medicine Research Program of Hebei Province (2021119)。
文摘The rapid spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) in recent years not only caused a global pandemic but resulted in enormous social,economic,and health burdens worldwide.Despite considerable efforts to combat coronavirus disease 2019(COVID-19),various SARS-CoV-2 variants have emerged,and their underlying mechanisms of pathogenicity remain largely unknown.Furthermore,effective therapeutic drugs are still under development.Thus,an ideal animal model is crucial for studying the pathogenesis of COVID-19 and for the preclinical evaluation of vaccines and antivirals against SARS-CoV-2 and variant infections.Currently,several animal models,including mice,hamsters,ferrets,and nonhuman primates(NHPs),have been established to study COVID-19.Among them,ferrets are naturally susceptible to SARS-CoV-2 infection and are considered suitable for COVID-19 study.Here,we summarize recent developments and application of SARS-CoV-2 ferret models in studies on pathogenesis,therapeutic agents,and vaccines,and provide a perspective on the role of these models in preventing COVID-19 spread.
基金supported by the National Natural Science Foundation of China (81571396 and 81771528)Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20170411090932146, JCYJ20170818110544730)。
文摘The mechanism of how SARS-CoV-2 causes severe multi-organ failure is largely unknown. Acute kidney injury(AKI) is one of the frequent organ damage in severe COVID-19 patients. Previous studies have shown that human renal tubule cells could be the potential host cells targeted by SARS-CoV-2. Traditional cancer cell lines or immortalized cell lines are genetically and phenotypically different from host cells. Animal models are widely used, but often fail to reflect a physiological and pathogenic status because of species tropisms. There is an unmet need for normal human epithelial cells for disease modeling. In this study, we successfully established long term cultures of normal human kidney proximal tubule epithelial cells(KPTECs) in 2 D and 3 D culture systems using conditional reprogramming(CR) and organoids techniques.These cells had the ability to differentiate and repair DNA damage, and showed no transforming property. Importantly, the CR KPTECs maintained lineage function with expression of specific transporters(SLC34 A3 and cubilin). They also expressed angiotensin-converting enzyme 2(ACE2), a receptor for SARS-CoV and SARS-CoV-2. In contrast, cancer cell line did not express endogenous SLC34 A3, cubilin and ACE2. Very interestingly, ACE2 expression was around twofold higher in 3 D organoids culture compared to that in 2 D CR culture condition. Pseudovirion assays demonstrated that SARS-CoV spike(S) protein was able to enter CR cells with luciferase reporter. This integrated 2 D CR and 3 D organoid cultures provide a physiological ex vivo model to study kidney functions, innate immune response of kidney cells to viruses, and a novel platform for drug discovery and safety evaluation.
文摘Global prevalence of coronavirus disease 2019(COVID-19)calls for an urgent development of anti-viral regime.Compared with the development of new drugs,drug repurposing can significantly reduce the cost,time,and safety risks.Given the fact that coronavirus harnesses spike protein to invade host cells through angiotensinconverting enzyme 2(ACE2),hence we see if any previous anti-virtual compounds can block spike-ACE2 interaction and inhibit the virus entry.The results of molecular docking and molecular dynamic simulations revealed that remdesivir exhibits better than expected anti-viral invasion potential against COVID-19 among the three types of compounds including remdesivir,tenofovir and lopinavir.In addition,a positive correlation between the surface area occupied by remdesivir and anti-viral invasion potential was also found.As such,the structure of remdesivir was modified by linking an N-benzyl substituted diamidine derivative to its hydroxyl group through an ester bond.It was found that this compound has a higher anti-viral invasion potential and greater specificity.
